Trellis Bioscience, Redwood City, CA
INDIRECT-ACTING LARGE MOLECULE ANTIBACTERIAL
TRL1068, a native human monoclonal antibody, disrupts bacterial biofilm by extracting a key scaffolding protein, thereby rendering the bacteria more susceptible to attack by the immune system as well as more sensitive to conventional antibiotics. TRL1068 has been shown to enhance antibiotic activity in highly-drug-resistant strains of Gram-positive and Gram-negative bacteria. The antibody was developed using Trellis’ platform technology, which integrates computerized microscopy with advanced nanomaterials for discovery of native human monoclonal antibodies directly from white blood cells of healthy blood donors. CARB-X funding will support antibody manufacturing for Phase 1 development.
Current Development Stage: Phase 1
CARB-X Investment: Initial investment of up to $3.2m with potential option payments up to $3.8m
Initial CARB-X Investment Date: October 1, 2019